Close
Achema middle east
swop processing & packaging

Lonza Widens Cell and Gene Therapy Suite with New Products

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

No New Drug Submissions by the FDA With Shutdown in Place

The Food and Drug Administration (FDA), which is already...

How to Tell if Your Loved One is Developing an Addiction

Watching a loved one change in ways you do...

The Future of Balding Treatments: What’s New in 2025

Are you balding or thinning out on top? It...

Genmab Buys Cancer Biotech Merus in $8B Oncology Deal

In a recent update, Genmab buys cancer biotech Merus...

Lonza widens cell and gene therapy suite by way of launching of two new products, which are – TheraPEAK AmpliCell Cytokines as well as TheraPEAK 293-GT Medium.

The additions happened to be aimed at elevating the scalability as well as consistency of advanced therapy production as per the Good Manufacturing Practice (GMP) conditions.

The TheraPEAK AmpliCell Cytokines happen to be designed in order to support immune cell expansion, activation, and, of course, differentiation. Manufactured through using a mammalian expression system, the cytokines get engineered for high biological activity as well as structural fidelity, hence providing advantages as compared to the bacterial systems when it comes to folding, glycosylation along with batch consistency. Lonza confirmed that the product is intended to enhance the predictability in research and also clinical manufacturing environments.

Meanwhile, TheraPEAK 293-GT Medium, which is chemically defined and also an animal-origin-free formulation, has gone on to be optimized for adeno-associated virus (AAV) production in suspension HEK293 cells. The company said that the medium happens to be compatible with the present transfection reagents as well as the AAV enhancers and at the same time also supports high full-to-empty capsid ratios, which happen to be an important metric when it comes to gene therapy vector production.

It is well to be noted that both the products happen to be a part of the TheraPEAK portfolio by Lonza, which, as per the company, has been used in FDA-approved therapies as well as across 130 clinical trials throughout the world.

Lonza’s Head of Bioscience, Specialized Modalities, Mike Goetter, said that the introduction of AmpliCell Cytokines as well as the 293-GT Medium to their TheraPEAK Range massively elevates their offering, and as Lonza widens cell and gene therapy suite, it gives them dependable solutions in order to support their drug development endeavors.

Latest stories

Related stories

No New Drug Submissions by the FDA With Shutdown in Place

The Food and Drug Administration (FDA), which is already...

How to Tell if Your Loved One is Developing an Addiction

Watching a loved one change in ways you do...

The Future of Balding Treatments: What’s New in 2025

Are you balding or thinning out on top? It...

Genmab Buys Cancer Biotech Merus in $8B Oncology Deal

In a recent update, Genmab buys cancer biotech Merus...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »